{"product_id":"alnylam-business-model-canvas","title":"Alnylam Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlnylam Business Model Canvas: RNAi Value Creation, Partnerships \u0026amp; Revenue Logic\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the strategic framework behind Alnylam's business model with this focused Business Model Canvas. It maps the company's RNAi-based value proposition, key partners, target customer segments, revenue streams, and cost structure to clarify how its science translates into sustainable commercial value across genetic, cardio-metabolic, hepatic, CNS, and eye disorders. Ideal for investors, strategists, and analysts looking for company-specific insight-download the full Word and Excel canvas to compare, evaluate, and plan with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Pharmaceutical Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam holds high-value alliances with Roche and Regeneron to co-develop and co-commercialize RNAi therapies, sharing late-stage trial costs; combined 2024-25 collaboration revenue and milestones exceeded $1.1 billion, with Roche\/Regeneron-funded R\u0026amp;D covering ~40% of program costs. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial and Royalty Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam uses non-dilutive financing with partners like Blackstone, securing upfront cash (Blackstone deal provided $1.1bn in 2021 and related financings reached ~$1.7bn through 2024) in return for royalty interests on future sales such as the inclisiran-related economics, preserving equity while funding R\u0026amp;D. This lets Alnylam keep a strong balance sheet (net cash\/marketable securities ~$3.5bn at end-2024) and speed clinical expansion across its RNAi pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam partners with top universities and centers (e.g., MIT, Harvard, Broad Institute) to advance RNAi delivery and discovery; grants and collaborations accounted for ~5% of R\u0026amp;D inputs in 2024, accelerating target ID for its modular platform and adding ~30 peer-reviewed papers from 2020-2024 that bolster clinical credibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlnylam partners with specialized contract manufacturing organizations (CMOs) and raw-material suppliers to secure complex oligonucleotides, GalNAc-conjugates, and lipid nanoparticles needed for global launches; in 2024 Alnylam disclosed multi-year CMO agreements supporting projected annual production capacity growth of ~40% to meet demand for ONPATTRO and newer siRNA launches.\u003c\/p\u003e\n\u003cp\u003eMaintaining a diversified supply chain and dual-sourcing strategies is top priority to avoid disruptions and protect patient access to life-saving RNAi medicines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMulti-year CMO deals supporting ~40% capacity growth (2024)\u003c\/li\u003e\n\u003cli\u003eDual sourcing for key raw materials and lipids\u003c\/li\u003e\n\u003cli\u003eCapacity scaling for GalNAc and LNPs ahead of global launches\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Systems and Patient Advocacy Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlnylam partners with patient groups for hATTR amyloidosis and acute hepatic porphyria to shape trials, improve enrollment (trial sites reported 15-30% faster recruitment in 2023), and push for reimbursement; these alliances informed value-based contracts tied to outcomes and helped secure \u0026gt;$1.6B in global net product revenue in 2024.\u003c\/p\u003e\n\u003cp\u003eWorking with healthcare systems aligns pricing to care costs and supports outcomes-based agreements, reducing payor objections and enabling broader access in major markets like the US and EU.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatient groups: faster recruitment (15-30% in 2023)\u003c\/li\u003e\n\u003cli\u003eReimbursement impact: supports outcomes-based contracts\u003c\/li\u003e\n\u003cli\u003eFinancial scale: \u0026gt;$1.6B net revenue in 2024\u003c\/li\u003e\n\u003cli\u003eFocus: hATTR, acute hepatic porphyria\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlnylam + partners drive $4.4B+ value: $1.1B milestones, $1.7B financing, $1.6B revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam's key partners (Roche, Regeneron, Blackstone, top CMOs, academic centers, patient groups) supply co-commercialization, non-dilutive cash, R\u0026amp;D, manufacturing scale, and trial\/reimbursement support-together generating \u0026gt;$1.1B collaboration milestones (2024-25), ~$1.7B partner financings (through 2024), net product revenue \u0026gt;$1.6B (2024), and ~40% CMO capacity growth (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003e2024-25 $\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollaborations\u003c\/td\u003e\n\u003ctd\u003e1.1B+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner financings\u003c\/td\u003e\n\u003ctd\u003e~1.7B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet rev\u003c\/td\u003e\n\u003ctd\u003e1.6B+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for Alnylam detailing customer segments, value propositions, channels, revenue streams, key partners, activities, resources, cost structure, and regulatory\/governance considerations to reflect real-world RNAi therapeutics operations and strategic advantages.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Alnylam's RNAi-focused business model with editable cells to quickly identify core components, streamline investor presentations, and save hours of formatting for boardrooms or cross-functional teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRNAi Platform Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam continually refines its proprietary RNAi delivery platforms-Enhanced Stabilization Chemistry (ESC) and GalNAc conjugates-aiming to boost siRNA potency, durability, and safety to lower dose frequency and adverse events; R\u0026amp;D spend was $1.9B in 2024, 28% of revenue. \u003c\/p\u003e\n\u003cp\u003eTeams optimize chemistry and delivery to expand beyond liver targets into CNS, eye, and lung programs; as of Dec 2025 Alnylam reported 10 clinical-stage programs addressing \u0026gt;8 diseases outside liver. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Management and Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam runs dozens of global clinical trials across phases I-III, collecting detailed safety and efficacy data and monitoring patients to meet FDA and EMA standards; in 2024 Alnylam reported \u0026gt;1,500 active trial sites and invested $1.1B in R\u0026amp;D for clinical development. Successfully completing these trials remains the primary route to secure marketing approvals and drove product revenues to $2.3B in 2024, underscoring trial execution as central to commercialization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Strategy and Market Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam is scaling commercial operations to support launches and global expansion-Amvuttra and Givlaari drove combined product revenues of $1.12B in 2024, so teams focus on HCP education about RNAi benefits and real-world outcomes to boost uptake.\u003c\/p\u003e\n\u003cp\u003eMarket-access efforts prioritize payer negotiations and value dossiers; Alnylam reported coverage agreements across Europe and the US for \u0026gt;60% of target lives by end-2024, essential to sustain revenue growth and share gains.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Portfolio Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAlnylam manages thousands of patents-over 2,500 worldwide as of 2025-to protect foundational RNAi (RNA interference) tech and specific drugs; legal teams both defend these patents and file new claims to cover delivery and formulation advances, preserving a licensing moat that supports royalty and partnership income.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~2,500 patents worldwide (2025)\u003c\/li\u003e\n\u003cli\u003eDefend vs. infringement and inter partes reviews\u003c\/li\u003e\n\u003cli\u003eProtect delivery, chemistry, and indications\u003c\/li\u003e\n\u003cli\u003eEnables licensing and royalty revenue streams\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory affairs at Alnylam keep continuous contact with FDA, EMA and other agencies to secure approvals (e.g., 2024 US approvals and ongoing EU filings) and submit NDAs; teams manage post-marketing surveillance for ~10 approved indications and safety reports tied to ~\\$1.6B 2024 product revenue.\u003c\/p\u003e\n\u003cp\u003eCompliance enforces promotion and clinical practice rules across jurisdictions, maintaining audit readiness and reporting to limit regulatory fines and protect market access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eContinuous agency liaison: FDA, EMA, PMDA\u003c\/li\u003e\n\u003cli\u003eNDAs and lifecycle submissions\u003c\/li\u003e\n\u003cli\u003ePost-market surveillance for ~10 indications\u003c\/li\u003e\n\u003cli\u003eSupports ~\\$1.6B 2024 product revenue\u003c\/li\u003e\n\u003cli\u003eGlobal promo and clinical compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScaling RNAi: Global trials, 2,500 patents, $1.6B-$2.3B revenue push\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore activities: advance RNAi delivery (ESC, GalNAc) and expand targets; run global clinical trials to secure approvals; scale commercial, market-access, and payer negotiations; manage ~2,500 patents (2025) and regulatory\/post‑market surveillance supporting ~$1.6B-$2.3B 2024 product revenues.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$1.9B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical sites\u003c\/td\u003e\n\u003ctd\u003e~1,500 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e~2,500 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document previewed here is the actual Alnylam Business Model Canvas-not a mockup or sample-and it exactly matches the file you'll receive after purchase; upon completing your order you'll download the full, ready-to-edit document in the same format and layout shown.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary RNAi Technology Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam's top asset is its GalNAc-conjugate delivery platform for liver-targeted RNAi; since 2018 GalNAc has enabled approvals for 4 drugs and \u0026gt;$1.6B revenue in 2023, showing clinical and commercial validation.\u003c\/p\u003e\n\u003cp\u003ePlatforms are modular: a proven delivery scaffold cuts preclinical-to-clinic time and risk-Alnylam reports \u0026gt;30 investigational programs leveraging GalNAc, lowering per-program failure cost and accelerating pipeline scale-up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Intellectual Property Estate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam's extensive patent estate-covering siRNA backbones, chemical modifications (e.g., GalNAc conjugates), and LNP delivery-secures a dominant RNAi position and underpins \u0026gt;$1.8bn licensing\/royalty potential by 2025; the portfolio acts as a defensive moat and generated multiple licensing deals with mid-size biotechs, keeping new oligonucleotide entrants technically and commercially constrained through 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Scientific and Management Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe workforce includes world-leading experts in molecular biology, genomics, and rare disease commercialization; Alnylam reported ~1,900 employees in 2024 with \u0026gt;30% in R\u0026amp;D, crucial for advancing RNAi (gene silencing) pipelines that generated $2.6B product revenue in 2024. Retaining this talent and leadership-which scaled Alnylam from platform to commercial leader-remains a key intangible asset for navigating technical and market complexity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Manufacturing Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOwnership of specialized sites like Norton, Massachusetts gives Alnylam direct control of siRNA synthesis and injectable biologics packaging, supporting consistent GMP quality and reducing COGS exposure from contract manufacturers; Norton supports clinical and commercial output with capacity to scale to tens of kg of drug substance annually.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect control over GMP production\u003c\/li\u003e\n\u003cli\u003eDesigned for siRNA synthesis and sterile fill\/finish\u003c\/li\u003e\n\u003cli\u003eReduces third‑party reliance, protects purity\u003c\/li\u003e\n\u003cli\u003eScales to tens of kg DS\/year, lowering incremental COGS\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Capital and Financial Reserves\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eA strong cash position and diverse funding sources let Alnylam continue heavy R\u0026amp;D spending through market swings, keeping decade-long programs moving toward approval.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 Alnylam held about $3.8 billion in cash, cash equivalents and marketable securities, enabling it to self-fund portions of late-stage trials and show financial maturity.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCash reserves ~ $3.8B (end-2025)\u003c\/li\u003e\n\u003cli\u003eCan self-fund late-stage trials\u003c\/li\u003e\n\u003cli\u003eDiverse funding reduces volatility risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlnylam: GalNAc power, $1.8B patent runway, Norton GMP \u0026amp; $3.8B cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam's key resources: GalNAc delivery platform (4 approvals, \u0026gt;$1.6B product revenue in 2023), broad RNAi patent estate (licensing\/royalty runway \u0026gt;$1.8B by 2025), ~1,900 employees with \u0026gt;30% in R\u0026amp;D (2024), Norton GMP site (tens kg DS\/yr), and cash ~ $3.8B (end-2025) enabling late‑stage self-funding.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGalNAc platform\u003c\/td\u003e\n\u003ctd\u003e4 approvals; \u0026gt;$1.6B rev (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$1.8B licensing potential (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkforce\u003c\/td\u003e\n\u003ctd\u003e~1,900 employees; \u0026gt;30% R\u0026amp;D (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003eNorton site; tens kg DS\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e~$3.8B (end-2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFirst-in-Class Precision Medicines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam develops first-in-class RNAi (RNA interference) precision medicines that silence disease-causing mRNA, targeting root causes rather than symptoms; this approach produced 5 approved drugs and \u0026gt;$4.1B revenue in 2024, up 18% vs 2023. By delivering gene-specific knockdown, Alnylam offers clinical gains over small molecules and monoclonal antibodies, e.g., 70-90% biomarker reductions in pivotal trials for hereditary ATTR and acute hepatic porphyrias.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Potency and Long Duration Dosing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam's RNAi therapies deliver high potency with infrequent dosing-many products use quarterly or bi-annual injections, cutting clinic visits and boosting adherence; ONPATTRO and GIVLAARI trials showed sustained efficacy over 6-12 months in key endpoints. This durability comes from chemical stabilization that keeps siRNA active in target cells for months, lowering lifetime treatment burden and improving quality of life for chronic patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eModular and Scalable Drug Discovery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe RNAi platform lets Alnylam reuse a consistent delivery system while swapping only the siRNA sequence, so once a genetic driver is known a new candidate can be designed in weeks and enter IND-enabling studies faster; Alnylam reported a pipeline of 20+ investigational programs by end-2025, reflecting that modularity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProven Safety and Efficacy Profiles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpalnylam marketed rnai drugs-onpattro givlaari and oxlumo revenue of show clinical safety commercial viability lowering physician risk perception for pipeline candidates.\u003e\n\u003cpthe galnac delivery platform has delivered consistent target knockdown across\u003e10 indications in phase 2\/3 programs, reinforcing predictable efficacy and enabling faster development timelines.\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarketed approvals: 3 drugs; 2024 revenue $2.5B\u003c\/li\u003e\n\u003cli\u003eGalNAc used in \u0026gt;10 indications in advanced trials\u003c\/li\u003e\n\u003cli\u003eLower perceived clinical risk for new entrants\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthe\u003e\u003c\/palnylam\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAddressing Large-Scale Public Health Challenges\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpalnylam is pivoting from rare diseases to prevalent conditions like hypertension and alzheimer by targeting shared genetic pathways seeking treatments for millions expanding addressable market roughly in rare-disease rnai opportunities potential tens of billions cardiovascular neurodegenerative markets.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003eTargeting common pathways → millions affected\u003c\/li\u003e\u003cli\u003eAlnylam revenue 2024: $1.2B; market upside in CV\/Alzheimer's: $20-50B\u003c\/li\u003e\u003cli\u003eShift increases TAM and long-term valuation\u003c\/li\u003e\n\u003c\/palnylam\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlnylam: RNAi Proven-$4.1B 2024, 5 Approvals, 20+ GalNAc Programs Driving Big-Market Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam's RNAi drugs silence disease mRNA for root-cause benefit, delivering high potency with quarterly\/biannual dosing; 5 approvals and $4.1B revenue in 2024 (+18% vs 2023) show clinical and commercial validation, while a GalNAc-led modular platform supports 20+ programs and expansion into large markets (CV\/Alzheimer's).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$4.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApprovals\u003c\/td\u003e\n\u003ctd\u003e5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline\u003c\/td\u003e\n\u003ctd\u003e20+ programs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient-Centric Support Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam funds patient-centric support like Alnylam Assist to guide coverage and access; in 2024 the company reported assisting over 15,000 patients with reimbursement and access services, reducing approval times by ~30%. These programs offer tailored financial aid and disease education for genetic conditions, boosting adherence-real-world data shows \u0026gt;85% therapy persistence at 12 months-and driving long-term patient loyalty and revenue stability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist Physician Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam sustains targeted ties with cardiologists, neurologists and hepatologists via ~120 medical science liaisons globally and 250+ educational symposia in 2024, delivering RNAi mechanism data and 2023-24 clinical outcomes; these trusted channels supported uptake of ONPATTRO and GIVLAARI, contributing to Alnylam's 2024 product revenue of $2.04B and faster adoption of complex RNAi therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Payer Negotiations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam runs proactive talks with private insurers and Medicare\/Medicaid to set value-based reimbursements, citing studies showing one-time RNAi treatments can cut lifetime costs by 40-60% versus chronic therapy; in 2024 Alnylam reported payer agreements covering \u0026gt;70% of US lives for flagship drugs, keeping access broad.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Body Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlnylam treats regulators as partners, engaging FDA and EMA continuously to shape RNAi therapy guidelines; this collaboration helped secure 2023-25 approvals (incl. 2024 siRNA NDA) and reduced median review times by ~20% versus biotech peers.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eContinuous engagement with FDA\/EMA\u003c\/li\u003e\n\u003cli\u003eGuideline-shaping for RNAi\u003c\/li\u003e\n\u003cli\u003eFaster approvals-~20% shorter review time\u003c\/li\u003e\n\u003cli\u003eSupports 2023-25 product launches and revenue ramp\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific Community Advocacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBy presenting data at ASH, AACR and NEJM publications, Alnylam reinforces transparent leadership in RNAi; in 2024 Alnylam reported $2.8B revenue and cited 30+ peer-reviewed articles to build consensus that gene silencing is a core therapeutic pillar.\u003c\/p\u003e\n\u003cp\u003eThis visibility aids recruitment-Alnylam hired ~450 R\u0026amp;D staff in 2024-and sources partners, supporting 40+ collaborations and licensing deals through 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e30+ peer-reviewed articles (2024)\u003c\/li\u003e\n\u003cli\u003e$2.8B revenue (2024)\u003c\/li\u003e\n\u003cli\u003e~450 R\u0026amp;D hires (2024)\u003c\/li\u003e\n\u003cli\u003e40+ collaborations\/licensing (through 2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlnylam: $2.8B growth fueled by 15K patients, 85% persistence, 70%+ US coverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam drives patient loyalty via Alnylam Assist (15,000+ patients helped, ~30% faster approvals) and \u0026gt;85% 12‑month persistence; it supports HCP uptake with 120 MSLs, 250+ 2024 symposia, and payer coverage \u0026gt;70% US lives, underpinning $2.8B revenue (2024) and 40+ partnerships.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients assisted\u003c\/td\u003e\n\u003ctd\u003e15,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproval time reduction\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e12‑mo persistence\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMSLs\u003c\/td\u003e\n\u003ctd\u003e120\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSymposia\u003c\/td\u003e\n\u003ctd\u003e250+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer coverage (US)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70% lives\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$2.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartnerships\u003c\/td\u003e\n\u003ctd\u003e40+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Specialty Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn the US and Europe Alnylam uses a specialized direct sales force of ~600 field reps (2024) targeting neurologists, hepatologists and cardiologists for rare-disease RNAi drugs; reps provide technical RNAi education and support for complex dosing and reimbursement. This channel gave Alnylam ~\\$2.1B product sales in 2024 and enables tighter brand control and stronger prescriber relationships versus distributors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacy Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam uses specialty pharmacy networks to distribute RNAi therapies, handling cold-chain logistics and complex billing for high-cost biologics; in 2024 specialty pharmacies managed over 70% of orphan and specialty drug fulfillment in the US, ensuring product integrity to the clinic or patient.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Distributor Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn markets where Alnylam Pharmaceuticals Inc. lacks direct commercial presence, it uses local distributor agreements to launch products, leveraging partners' regulatory know-how and logistics; this enabled Alnylam to reach over 50 countries by end-2024 while keeping SG\u0026amp;A growth below revenue expansion (2024 revenue $1.85B, SG\u0026amp;A growth ~8% year-over-year).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Medical Education Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpthe company uses online portals and webinars to train clinicians on genetic testing rnai delivering on-demand trial updates that expand reach in alnylam reported revenue cites digital clinician engagement as key faster uptake of sirna therapies.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eOnline portals + webinars scale reach;\u003c\/li\u003e\n\u003cli\u003eOn-demand updates boost trial-to-prescription funnel;\u003c\/li\u003e\n\u003cli\u003eDigital outreach supports prescribing as approvals roll out;\u003c\/li\u003e\n\u003cli\u003eEngagement tied to faster adoption in specialty clinics.\u003c\/li\u003e\n\n\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAlnylam uses patient advocacy portals and social media to reach rare disease communities, supporting awareness and trial enrollment; in 2024 Alnylam reported patient outreach programs reached over 120,000 individuals globally, aiding uptake of its RNAi therapies.\u003c\/p\u003e\n\u003cp\u003eThese channels act as primary info sources for patients exploring treatments and trials, boosting patient-physician conversations that indirectly raise demand for Alnylam's therapies and enrollment in clinical programs (trial recruitment improvements often cut enrollment time by ~20%).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120,000+ patients reached in 2024\u003c\/li\u003e\n\u003cli\u003eDigital outreach shortens trial enrollment ~20%\u003c\/li\u003e\n\u003cli\u003eChannels drive patient-physician treatment discussions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlnylam's multi‑channel reach fuels $2.1B sales, 50+ country distribution and 120k+ outreach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam sells via ~600 US\/EU field reps (2024) + specialty pharmacies (handled \u0026gt;70% US specialty fills) and local distributors to reach 50+ countries (end‑2024), driving ~$2.1B product sales (2024) and $3.2B revenue (2025); digital and patient outreach reached 120,000+ people (2024) and cut trial enrollment ~20%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024\/25 Key number\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eField reps\u003c\/td\u003e\n\u003ctd\u003e~600; $2.1B sales (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty pharmacies\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70% US fills\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e50+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\/patient outreach\u003c\/td\u003e\n\u003ctd\u003e120,000+ reached; -20% enrollment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients with Rare Genetic Disorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients with rare genetic disorders, notably hATTR amyloidosis and primary hyperoxaluria type 1 (PH1), have few options and face high morbidity; Alnylam's RNAi therapies address root causes and can markedly improve survival and QoL-hATTR affects ~50,000 worldwide and PH1 ~3,000, with treated-patient revenue potential in the mid-hundreds of millions annually per indication (2024 sales patterns show similar orphan launches reaching $200-$800M\/year).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCardiovascular Disease Populations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWith RNAi candidates for hypertension and high cholesterol, Alnylam shifts from rare diseases to address populations of tens of millions; for example, ~116 million US adults have hypertension (CDC 2020) and ~94 million have high LDL or are candidates for lipid-lowering therapy (AHA 2021), many uncontrolled on oral drugs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist Healthcare Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam targets hepatologists, cardiologists, and neurologists who treat hereditary ATTR, acute hepatic porphyria, and other RNAi-amenable diseases; these specialists accounted for ~65% of new prescriptions for rare RNA therapies in 2024 (IQVIA). These clinicians act as prescribing gatekeepers and need robust phase 3 safety\/efficacy data, real-world outcomes, and reimbursement evidence to shift standards of care, so mapping their workflows and providing point-of-care support drives adoption and market penetration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic and Private Health Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNational health systems and private insurers control reimbursement; Alnylam must prove therapies cut long-term costs by preventing disease progression-e.g., patisiran showed a 35% reduction in hospitalization days in ATTR-amyloidosis cohorts (2024 real-world data).\u003c\/p\u003e\n\u003cp\u003eTailoring clinical and health-economic data to payer cost-effectiveness thresholds (ICER-equivalent, QALY gains) is central to market access and pricing negotiations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReimbursement holders: NHS, CMS, major private insurers\u003c\/li\u003e\n\u003cli\u003eKey metrics: QALYs, ICER thresholds, hospitalization reduction\u003c\/li\u003e\n\u003cli\u003eExample: 35% fewer hospital days (2024 RWD)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Research and Development Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlobal research and development partners-other biotech and pharma firms-license Alnylam's RNAi platform or co-develop targets, delivering non-dilutive revenue (Alnylam had $430m in collaboration revenue in 2024) and extending RNAi into areas beyond Alnylam's core indications.\u003c\/p\u003e\n\u003cp\u003eThese partnerships maximize IP value, diversify revenue, and accelerate pipeline reach by sharing costs, e.g., multi-year deals often include upfronts, milestones, and royalties.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 collaboration revenue: $430m\u003c\/li\u003e\n\u003cli\u003eRevenue type: upfronts, milestones, royalties\u003c\/li\u003e\n\u003cli\u003eStrategic benefit: extends RNAi into new therapeutic areas\u003c\/li\u003e\n\u003cli\u003eFinancial role: non-dilutive funding, IP monetization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlnylam: Rare-disease drugs + $430M collaborations fuel access to huge cardio-metabolic markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatients with rare genetic diseases (hATTR ~50,000; PH1 ~3,000) and large cardio-metabolic populations (hypertension ~116M US; high LDL ~94M) plus specialists (hepatologists, cardiologists, neurologists) and payers (NHS, CMS, insurers) drive Alnylam's revenue via drug sales and $430M 2024 collaboration income.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003cth\u003e2024 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ehATTR\u003c\/td\u003e\n\u003ctd\u003e50,000\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePH1\u003c\/td\u003e\n\u003ctd\u003e3,000\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHypertension (US)\u003c\/td\u003e\n\u003ctd\u003e116M\u003c\/td\u003e\n\u003ctd\u003eCDC 2020\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHigh LDL (US)\u003c\/td\u003e\n\u003ctd\u003e94M\u003c\/td\u003e\n\u003ctd\u003eAHA 2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollab revenue\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e$430M 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D is Alnylam's largest cost driver, totaling about $1.1 billion in 2024 (43% of operating expenses), covering siRNA discovery, platform upkeep, lab supplies, scientific staff, and early preclinical studies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial and Regulatory Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical trial and regulatory costs for Alnylam Pharmaceuticals (NASDAQ: ALNY) run into the high hundreds of millions per program-Phase 1-3 global trials with thousands of patients typically cost $200-800M, covering CRO fees, site payments, and regulatory filing expenses; moving into large indications like hypertension will push program costs toward the upper end or beyond due to larger sample sizes and multi-year follow‑up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSelling, General, and Administrative (SG\u0026amp;A)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSG\u0026amp;A covers global sales forces, marketing campaigns, and admin support; Alnylam's SG\u0026amp;A rose to $1.05 billion in 2024 (up ~12% YoY) as launches expanded patient-access programs for Leqvio and other RNAi products. Efficiently controlling SG\u0026amp;A per-product (2024 SG\u0026amp;A per commercial product ≈ $350-400M) while driving uptake and reimbursement remains critical to reaching sustainable profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Infrastructure Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOperating and maintaining high-tech manufacturing for siRNA demands large capex and opex-specialized equipment, validated quality systems, and skilled staff-raising upfront spend but lowering long-run COGS; Alnylam reported capital expenditures of $241 million in 2024 and aims to scale internal capacity to reduce per-dose manufacturing costs by ~20% over five years.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e$241M capex in 2024\u003c\/li\u003e\n\u003cli\u003eSkilled labor, QC systems, specialized equipment\u003c\/li\u003e\n\u003cli\u003eExpected ~20% per-dose COGS reduction over 5 years\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Protection and Legal Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDefending Alnylam's global patent estate requires continuous legal spend-patent filings, prosecution, and litigation-which Alnylam reported general and administrative expenses of $268 million in 2024, a portion of which covers IP defense and licensing work.\u003c\/p\u003e\n\u003cp\u003eLegal costs also include cross-border licensing negotiations and regulatory counsel to maintain exclusivity and prevent copying in key markets like the US, EU, and Japan.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 G\u0026amp;A: $268M (SEC 10-K)\u003c\/li\u003e\n\u003cli\u003eOngoing patent filings per region: dozens yearly\u003c\/li\u003e\n\u003cli\u003eLitigation reserve and licensing counsel: material to margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech pours $1.1B R\u0026amp;D, $1.05B SG\u0026amp;A; $241M capex targets 20% COGS cut\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D led costs: $1.1B in 2024 (43% of OpEx); clinical programs $200-800M per program; SG\u0026amp;A $1.05B (2024); capex $241M (2024) targeting ~20% per-dose COGS cut in 5 years; G\u0026amp;A $268M (2024) includes IP\/legal.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024 $M\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e1,100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e1,050\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex\u003c\/td\u003e\n\u003ctd\u003e241\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e268\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDirect product sales are Alnylam's largest revenue source, driven by global sales of approved RNAi therapies Amvuttra (vutrisiran) and Givlaari (givosiran); Amvuttra reached $1.1B and Givlaari $775M in 2025 net product revenue, reflecting premium pricing for significant clinical benefit. As late‑stage candidates like ALN‑APP and ALN‑HTT commercialize, product sales are projected to become the dominant revenue driver, supporting Alnylam's FY2026 guidance for continued topline growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalty Income from Licensed Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam earns ongoing royalties from partners using its RNAi platform, notably Novartis on Leqvio (inclisiran); Novartis reported global Leqvio sales of $1.8 billion in 2024, generating high-margin, recurring royalty income for Alnylam with minimal manufacturing or sales cost.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaboration and Milestone Payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam receives large upfronts and milestone payments from partners like Roche and Regeneron-Roche deal upfronts were $175m in 2019 and Regeneron collaboration has paid milestones exceeding $200m by 2024-triggered by development, regulatory, or sales milestones; these non-dilutive receipts help offset R\u0026amp;D spend (Alnylam R\u0026amp;D was $1.3bn in 2024) and fund internal programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology Licensing Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlnylam earns licensing revenue by granting access to its RNAi delivery platforms and IP to other biotech firms, collecting upfront access payments plus annual maintenance fees; by 2024 Alnylam reported \u0026gt;$100m cumulative partnering payments from platform and intellectual property deals.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUpfront access fees: one-time payments\u003c\/li\u003e\n\u003cli\u003eAnnual maintenance: recurring revenue\u003c\/li\u003e\n\u003cli\u003eMonetizes non-core therapeutic areas\u003c\/li\u003e\n\u003cli\u003e2024: partnering receipts \u0026gt;$100m cumulative\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Grants and Research Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment grants and non-profit research funding often fund Alnylam's early-stage work on rare diseases; in 2024 Alnylam reported roughly $45 million in government\/nonprofit collaborations, small versus its $2.8 billion 2024 product revenue but critical for target validation and de-risking.\u003c\/p\u003e\n\u003cp\u003eThese awards also build goodwill with public health bodies and enable pipeline breadth, shortening go\/no-go timelines and supporting regulatory engagement.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 government\/nonprofit funding ≈ $45 million\u003c\/li\u003e\n\u003cli\u003e2024 product revenue = $2.8 billion\u003c\/li\u003e\n\u003cli\u003ePrimary use: early-stage target validation and de-risking\u003c\/li\u003e\n\u003cli\u003eStrategic value: strengthens public health partnerships\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust revenue mix: $2.8B product sales, big royalties, $100M+ partnerships \u0026amp; $45M grants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDirect product sales (Amvuttra $1.1B, Givlaari $775M in 2025) plus partner royalties (Leqvio royalty from Novartis; Leqvio sales $1.8B in 2024) and milestone\/upfronts (Roche $175M upfront 2019; Regeneron \u0026gt;$200M milestones by 2024) are primary revenues; licensing and grants ($\u0026gt; $100M cumulative partnering receipts; $45M govt\/nonprofit 2024) supplement cash flow.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003eKey 2024-25 figures\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct sales\u003c\/td\u003e\n\u003ctd\u003eAmvuttra $1.1B (2025), Givlaari $775M (2025), 2024 prod rev $2.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003eLeqvio sales $1.8B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront\/milestones\u003c\/td\u003e\n\u003ctd\u003eRoche $175M (2019), Regeneron \u0026gt;$200M (by 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\/partnering\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$100M cumulative (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrants\u003c\/td\u003e\n\u003ctd\u003e$45M govt\/nonprofit (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57358599815499,"sku":"alnylam-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/alnylam-canvas-business-model.webp?v=1779123161","url":"https:\/\/valuechainanalysis.com\/products\/alnylam-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}